Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies

Jia Yang; Junjie Shangguan; Aydin Eresen; Yu Li; Jian Wang; Zhuoli Zhang

doi:10.1016/j.prp.2019.152691

Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies

Jia Yang, Junjie Shangguan, Aydin Eresen, Yu Li, Jian Wang, Zhuoli Zhang^*

^*Corresponding author for this work

Radiology

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

Despite significant advances over the past decades of research, pancreatic cancer (PC) continues to have the worst 5-year survival of any malignancy. Dendritic cells (DCs) are the most potent professional antigen-presenting cells and are involved in the induction and regulation of antitumor immune responses. DC-based immunotherapy has been used in clinical trials for PC. Although safety, efficacy, and immune activation were reported in patients with PC, DC vaccines have not yet fulfilled their promise. Additional strategies for combinatorial approaches aimed to augment and sustain the antitumor specific immune response elicited by DC vaccines are currently being investigated. Here, we will discuss DC vaccination immunotherapies that are currently under preclinical and clinical investigation and potential combination approaches for treating and improving the survival of PC patients.

Original language	English (US)
Article number	152691
Journal	Pathology Research and Practice
Volume	215
Issue number	12
DOIs	https://doi.org/10.1016/j.prp.2019.152691
State	Published - Dec 2019

Keywords

Combination therapies
Dendritic cells
Pancreatic cancer
Vaccine

ASJC Scopus subject areas

Pathology and Forensic Medicine
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.prp.2019.152691

Cite this

@article{50b81e9a83bd4d7eb6162ce871be97ab,

title = "Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies",

abstract = "Despite significant advances over the past decades of research, pancreatic cancer (PC) continues to have the worst 5-year survival of any malignancy. Dendritic cells (DCs) are the most potent professional antigen-presenting cells and are involved in the induction and regulation of antitumor immune responses. DC-based immunotherapy has been used in clinical trials for PC. Although safety, efficacy, and immune activation were reported in patients with PC, DC vaccines have not yet fulfilled their promise. Additional strategies for combinatorial approaches aimed to augment and sustain the antitumor specific immune response elicited by DC vaccines are currently being investigated. Here, we will discuss DC vaccination immunotherapies that are currently under preclinical and clinical investigation and potential combination approaches for treating and improving the survival of PC patients.",

keywords = "Combination therapies, Dendritic cells, Pancreatic cancer, Vaccine",

author = "Jia Yang and Junjie Shangguan and Aydin Eresen and Yu Li and Jian Wang and Zhuoli Zhang",

note = "Funding Information: This study was supported by the National Cancer Institute (grants R01CA209886 , R01CA196967 ), by the key research and development program of Tianjin Municipal Science and Technology Commission ( 17YFZCSY00870 ), by 2019 Harold E. Eisenberg Foundation Scholar Award, and by the Fishel Fellowship Award at the Robert H. Lurie Comprehensive Cancer Center. Appendix A Publisher Copyright: {\textcopyright} 2019 Elsevier GmbH",

year = "2019",

month = dec,

doi = "10.1016/j.prp.2019.152691",

language = "English (US)",

volume = "215",

journal = "Pathology Research and Practice",

issn = "0344-0338",

publisher = "Urban und Fischer Verlag GmbH und Co. KG",

number = "12",

}

TY - JOUR

T1 - Dendritic cells in pancreatic cancer immunotherapy

T2 - Vaccines and combination immunotherapies

AU - Yang, Jia

AU - Shangguan, Junjie

AU - Eresen, Aydin

AU - Li, Yu

AU - Wang, Jian

AU - Zhang, Zhuoli

N1 - Funding Information: This study was supported by the National Cancer Institute (grants R01CA209886 , R01CA196967 ), by the key research and development program of Tianjin Municipal Science and Technology Commission ( 17YFZCSY00870 ), by 2019 Harold E. Eisenberg Foundation Scholar Award, and by the Fishel Fellowship Award at the Robert H. Lurie Comprehensive Cancer Center. Appendix A Publisher Copyright: © 2019 Elsevier GmbH

PY - 2019/12

Y1 - 2019/12

N2 - Despite significant advances over the past decades of research, pancreatic cancer (PC) continues to have the worst 5-year survival of any malignancy. Dendritic cells (DCs) are the most potent professional antigen-presenting cells and are involved in the induction and regulation of antitumor immune responses. DC-based immunotherapy has been used in clinical trials for PC. Although safety, efficacy, and immune activation were reported in patients with PC, DC vaccines have not yet fulfilled their promise. Additional strategies for combinatorial approaches aimed to augment and sustain the antitumor specific immune response elicited by DC vaccines are currently being investigated. Here, we will discuss DC vaccination immunotherapies that are currently under preclinical and clinical investigation and potential combination approaches for treating and improving the survival of PC patients.

AB - Despite significant advances over the past decades of research, pancreatic cancer (PC) continues to have the worst 5-year survival of any malignancy. Dendritic cells (DCs) are the most potent professional antigen-presenting cells and are involved in the induction and regulation of antitumor immune responses. DC-based immunotherapy has been used in clinical trials for PC. Although safety, efficacy, and immune activation were reported in patients with PC, DC vaccines have not yet fulfilled their promise. Additional strategies for combinatorial approaches aimed to augment and sustain the antitumor specific immune response elicited by DC vaccines are currently being investigated. Here, we will discuss DC vaccination immunotherapies that are currently under preclinical and clinical investigation and potential combination approaches for treating and improving the survival of PC patients.

KW - Combination therapies

KW - Dendritic cells

KW - Pancreatic cancer

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85074491044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074491044&partnerID=8YFLogxK

U2 - 10.1016/j.prp.2019.152691

DO - 10.1016/j.prp.2019.152691

M3 - Review article

C2 - 31676092

AN - SCOPUS:85074491044

SN - 0344-0338

VL - 215

JO - Pathology Research and Practice

JF - Pathology Research and Practice

IS - 12

M1 - 152691

ER -

Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this